

**Innovative Medicines Initiative** 

### The Innovative Medicines Initiative: Building new models of collaborative research across Europe

Elisabetta Vaudano IMI, Belgium



www.imi.europa.eu

efpia

### What is IMI ?



#### An European Public-Private Partnership Focused on Needs Common to Pharmaceutical Industry and Patients







# The Innovative Medicines Initiative: the Largest PPP in Life Sciences R&D



**Innovative Medicines Initiative** 

\* Research performed by EFPIA member companies

= in kind contribution

IMI Research funding for

Academia, SMEs, patients organisations, Regulatory Authorities, etc.



#### **IMI Research Projects**



### **EFPIA Member Companies**



#### Participating companies (September 2010):










- Making the pharmaceutical R&D process faster and more effective, rather than directly delivering new drugs
- Accelerating the development of safer and more effective medicines for patients in Europe
- Improving the environment for pharmaceutical R&D in Europe



Boosting the biopharmaceutical sector in Europe





9th March 2011, Barcelona Spain





Efforts to discover and develop new drugs for brain disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful, some of the reasons being...

....Most brain disorders are heterogeneous and multi-factorial

.....Target validation is challenging

....Complexity of symptoms is not simply the sum of its parts

.....Diagnosis is based on subjective criteria




Animal models are inadequate



### ....Current R&D Models Show no Significant Impact on R&D Innovation





Munos B., Nature Reviews Drug Discovery 8, 959-968 (December 2009)



# The Health-care Ecosystem is changing....




- Health care reform and health IT, are driving the system to include many companies not traditionally involved in the health care business.
- Patients from been traditionally relatively passive participants in health delivery are been empowered by technological progress to become educated super-consumers with a much more active role in management of their health care.



## The New Environment of "Big Pharma"



**Innovative Medicines Initiative** 







#### Open Innovation

#### • Pre-competitive research






# Open Industry-Academia Networks are Key to Achieve Innovative Medicines

#### Open innovation networks between academia and industry: an imperative for breakthrough therapies

Teri Melese, Salima M Lin, Julia L Chang & Neal H Cohen

The demand to bring transformative therapeutics to patients and the escalating costs of doing so are driving the life science industry to seek collaborations with academia to stimulate innovation. Despite the opportunities afforded by working together, companies and universities lack a systematic approach for capturing the full potential of such relationships. Detailed here are a few suggested strategies to help these collaborations succeed.

The term 'open innovation' was coined by Henry Chesbrough to describe "how useful knowledge and technology was becoming increasingly widespread," such that newly developing technologies and products benefited from integrating knowledge and expertise from multiple sources<sup>1</sup>. He also made the case that the economics of innovation is a key driver for companies to open their innovation process<sup>1,2</sup>. Pharmaceutical and large biotechnology companies, as an example, increased their research and development (P.SD) spend



VOLUME 15 NUMBER 5 MAY 2009 NATURE MEDICINE





## Precompetitive Research to Boost Innovation in Biomedicine

nature publishing group



**NEWS & VIEWS** 

#### MACROSCOPY

#### Precompetitive Research: A New Prescription for Drug Development?

J Woodcock<sup>1</sup>

Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.




Clinical pharmacology & Therapeutics | VOLUME 87 NUMBER 5 | MAY 2010















#### IMI is an Industry driven initiative



**Innovative Medicines Initiative** 







#### **EMA supports IMI activities**





London, 23 September 2009 Doc. Ref. EMEA/585460/2009

#### The European Medicines Agency's participation in Innovative Medicines Initiative (IMI) Research projects

#### The European Medicines Agency's position regarding participation in IMI consortia:

The agency fully supports the overall goals of IMI, recognising its benefits for public health. We may therefore be willing and able to participate in select projects, contingent upon a number of considerations. These include:

- Considerations of resources: Participation in an IMI project may be labour intensive and we
  need to be conscious of its internal resource constraints.
- *Potential for conflicts of interest (CoI):* Since IMI projects will be designed to, *inter alia*, develop methodologies to be applied to drug development (e.g. biomarkers, novel approaches to analysis of clinical trials, etc), it is probable that some of these novel methodologies will, at a later stage, become part of a marketing authorisation dossier or a scientific advice procedure for e.g. biomarker qualification that will be assessed by the European Medicines Agency's Scientific Committees and Working Parties. This may create a situation of potential CoI.
- *Relevance of our contribution to the consortium:* We recognise that participation of (a) regulatory agency(ies) is critical for some but not all IMI call topics and consortia.







N ENGL J MED 362: 865-869, March 11, 2010

The NEW ENGLAND JOURNAL of MEDICINE

# Perspective

#### The Missing Voice of Patients in Drug-Safety Reporting

Ethan Basch, M.D.

A patient wants to know about symptoms she may have from a prescription drug she is taking. Consulting the label's "Adverse Reactions" section, she finds a wealth of data. Little does she realize that

drug-development cycle if reporting by patients were standard practice.

Before a drug has received marketing approval from the Food and Drug Administration (FDA),





	Call 1	Call 2	Total
Projects	15	8	23
<b>EFPIA Companies</b>	21	21	23
Academic teams	195	103	298
SME teams	24	23	47
Patients' organisat.	9	2	11
Total Budget (M€)	281	172	453



#### **IMI Four Strategic Pillars**










#### First call (2008) funded projects



15 Projects Total budget: 281 M€

3 Neuroscience Projects

Total budget nearly 60 M€



9th March 2011, Barcelona Spain





- Early prediction of drug-induced liver injury
- Risk minimization of antibodies to biopharmaceuticals
- Immunosafety of vaccines
- Translational research on autism spectrum disorders
- Personalized medicine in type II diabetes
- New strategies to treat tuberculosis



Patient awareness on pharmaceutical innovation





anovative Medicines Initiative

# nature medicine

#### Mechanism matters

The path of drug development is fraught with hurdles. Gaining a clear understanding of how a drug works before it enters clinical trials is the intelligent route to drug discovery and could increase the likelihood for drug success.

The percent of drugs that enter clinical trials are eventually approved. For a drug to gain FDA approval, it must be safe and show some efficacy. Because the FDA does not require any understanding of the mechanism by which a drug acts, it could be tempting to move into clinical trials without this knowledge. However, this may set the stage for failure. An investigational

It is true that we use many highly prescribed drugs without a clear idea of how they work—which targets they hit, what processes they alter and which of these actions are required for therapeutic efficacy. For instance, lithium, used to treat bipolar disorder, modulates many molecular targets, but which—or how many—of these are required for its beneficial effects is uncertain. Nevertheless, understanding a drug's mechanism could guide drug development and help to prevent late-stage failures such as Dimebon's.




nature medicine volume 16 | number 4 | April 2010: 347



## The Translational Process of Drug R&D







A. F. Cohen, Nature Reviews Drug Discovery 9, 856-865 (2010)



# Biomarkers are Critical for the R&D of Innovative Drugs




# No drug candidate should enter the clinic without a species-independent biomarker as the central element of translational medicine





## The Translational Process of Drug R&D





A. F. Cohen, Nature Reviews Drug Discovery 9, 856-865 (2010)







## Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development



Advancing science and treatment of Alzheimer's Disease

http://www.alzheimer-europe.org/FR/Research/PharmaCog





**Innovative Medicines Initiative** 

# Thank you for your attention!



